Issued Patents 2018
Showing 1–10 of 10 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 10065961 | Chiral N-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof | Guillaume Dutheuil, Graeme L. Fraser, Marie-Odile Roy, Mohamed El Bousmaqui, Frederic Batt | 2018-09-04 |
| 10065960 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | Marie-Odile Roy, Graeme L. Fraser, Guillaume Dutheuil | 2018-09-04 |
| 10040751 | Intermediates for macrocyclic compounds | Eric Marsault, Kamel Benakli, Mark L. Peterson, Sylvie Beaubien, Luc Ouellet +2 more | 2018-08-07 |
| 10030025 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists | Guillaume Dutheuil, Graeme L. Fraser | 2018-07-24 |
| 10017468 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | Didier Schils, Ludivine Zoute, Julien Parcq | 2018-07-10 |
| 9987274 | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists | Guillaume Dutheuil, Graeme L. Fraser | 2018-06-05 |
| 9969745 | N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders | Guillaume Dutheuil, Graeme L. Fraser | 2018-05-15 |
| 9969738 | N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders | Guillaume Dutheuil, Graeme L. Fraser | 2018-05-15 |
| 9949949 | Macrocyclic ghrelin receptor modulators and methods of using the same | Graeme L. Fraser, Kamel Benakli, Eric Marsault, Mark L. Peterson | 2018-04-24 |
| 9926325 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | Marie-Odile Roy, Graeme L. Fraser, Guillaume Dutheuil | 2018-03-27 |